ArticleChemical communications (Cambridge, England)2013
Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation.
Article in Chemical communications (Cambridge, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 72 citations in OpenAlex.
- Design of New Daunorubicin Derivatives with High Cytotoxic Potential.International journal of molecular sciences · 2025Article
- The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi-Targeting Drugs Through Materials Engineering: A Possible Future Scenario.Small science · 2024Article
- Orthogonal Hydroxyl Functionalization of cGAMP Confers Metabolic Stability and Enables Antibody Conjugation.ACS central science · 2023Article
- Introduction to Antibody-Drug Conjugates.Antibodies (Basel, Switzerland) · 2021Review
- New Bifunctional Chelators Incorporating Dibromomaleimide Groups for Radiolabeling of Antibodies with Positron Emission Tomography Imaging Radioisotopes.Bioconjugate chemistry · 2021Article
- Causes, consequences, and therapy of tumors acidosis.Cancer metastasis reviews · 2019Review
- Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals.Drug discovery today. Technologies · 2018Review
- Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering.Chemical science · 2017Article
- Site-Selective Disulfide Modification of Proteins: Expanding Diversity beyond the Proteome.Chemistry (Weinheim an der Bergstrasse, Germany) · 2016Review
- Next-generation disulfide stapling: reduction and functional re-bridging all in one.Chemical science · 2016Article
- Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Pharmaceutical research · 2015Review
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.Nature communications · 2015Article
- Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging.Organic & biomolecular chemistry · 2014Article
- Homogeneous bispecifics by disulfide bridging.Bioconjugate chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
In this communication we describe a novel acid-cleavable linker strategy for antibody-drug conjugation. Functional disulfide bridging of the single interchain disulfide bond of a trastuzumab Fab fragment yields a homogeneous antibody-drug conjugate bearing a thiomaleamic acid linker. This linker is stable at physiological pH and temperature, but quantitatively cleaves at lysosomal pH to release the drug payload.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.